Faron Pharmaceuticals Appoints Jurriaan Dekkers as CFO
Faron Pharmaceuticals Ltd , a clinical-stage biopharmaceutical company, announces the appointment of Jurriaan Dekkers as the company's Chief Financial Officer (CFO) as of 1 December 2025.
Dekkers brings more than 20 years of experience in biopharma and healthcare companies. Most recently, he has been the CFO at ProQR Therapeutics, a biotechnology company developing RNA therapies for severe unmet medical needs.
Prior to that, he served as CFO of AstraZeneca in the Netherlands and CEO of Acerta Pharma (part of the AstraZeneca Group). He has also held global and European finance roles at DaVita Medical Group, a US-listed international healthcare provider, and Sandvik, amongst others.
He currently serves as a Supervisory Board member and Audit Committee Member at Stichting Kinderpostzegels in the Netherlands.
Also Read: SCO Summit 2025: Outcomes of Modi-Xi Meeting
Dekkers holds a MSc. in Economics from the Erasmus University Rotterdam, the Netherlands, and is a Certified Public Auditor (Register Accountant, RA) graduate from the Erasmus University Rotterdam.
Also Read: A Brief History of India's Transformation Under PM Narendra Modi
"We are very happy to welcome Jurriaan into Faron's team in this exciting growth phase ofFaron. His experience and proven track record of fundraising and strategic and commercial growth initiatives will support the advancement of our lead asset bexmarilimab as it enters the registrational study", says Dr. Juho Jalkanen, CEO of Faron.
The Company's current CFO Yrjö Wichmann will be retiring having played a key role in supporting the Company's strategic transition and growth over a number of years. Wichmann will remain with the Company for a transitional period until end of 1Q2026 to ensure continuity.
Also Read: 5 Latest CHRO Appointments in Global Corporations
Dr. Juho Jalkanen says, "I would like to thank Yrjö for his great contributions to Faron over the years. Yrjö has had a key role both in the early stages of the Company as well as the more recent phases of growth and transition. Yrjö is an essential part of Faron's history and the spirit of the Company. We will miss him, and wish him all the best in his retirement."